(Q53824259)

English

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

secondary progressive multiple sclerosis

0 references

multiple sclerosis

0 references

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

Finn Sellebjerg

object named as

Finn Sellebjerg

16

0 references

Hans-Peter Hartung

12

object named as

Hans-Peter Hartung

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

0 references

1 reference

ORCID Public Data File 2021

1 reference

ORCID Public Data File 2021

1 reference

ORCID Public Data File 2021

author name string

Raju Kapoor

1

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Pei-Ran Ho

2

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Nolan Campbell

3

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Ih Chang

4

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Aaron Deykin

5

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Fiona Forrestal

6

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Nisha Lucas

7

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Bei Yu

8

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Douglas L Arnold

9

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Mark S Freedman

10

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Myla D Goldman

11

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Eva Kubala Havrdová

13

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Douglas Jeffery

14

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Aaron Miller

15

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Diego Cadavid

17

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Dan Mikol

18

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Deborah Steiner

19

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

ASCEND investigators

20

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

publication date

12 March 2018

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

17

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

5

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

405-415

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Defining the clinical course of multiple sclerosis: the 2013 revisions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Can the ABILHAND handle manual ability in MS?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Hand dexterity and direct disease related cost in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2818%2930069-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(18)30069-3

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 May 2018

http://europepmc.org/abstract/MED/29545067

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53824259&oldid=1582622619"